Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Company Overview - Vor Bio is a clinical-stage cell and genome engineering company focused on changing the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant [5] Key Appointment - Mr. Erez Kalir has been appointed to Vor Bio's Board of Directors, representing a new seat created in connection with a recent private investment in public equity financing (PIPE) led by Reid Hoffman [1] - Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman’s investment fund [1] Mr. Kalir's Background - Mr. Kalir has extensive experience as an investor, entrepreneur, and thought leader in life sciences and technology [2] - He is currently the Managing Member of Martial Eagle Fund and a Venture Partner at FJ Labs, known for early-stage venture investments [2] - Mr. Kalir has authored the influential Biotech Frontiers newsletter, providing analysis on cutting-edge biotech companies [2] - His educational background includes an MSc in cell biology from Magdalen College, Oxford, a JD from Yale Law School, and an A.B. with highest honors from Stanford University [4] Strategic Vision - Dr. Robert Ang, President and CEO of Vor Bio, expressed excitement about Mr. Kalir's appointment, highlighting his extensive biotech experience and track record in fostering innovation [3] - Matthew R. Patterson, Chairman of Vor Bio, welcomed Mr. Kalir and emphasized the importance of his contributions as the company advances its clinical programs and strategic vision [3] Future Goals - Mr. Kalir expressed his commitment to working with Vor Bio's management team to advance their trem-cel platform and VCAR33 through the regulatory approval process, aiming for life-changing impacts for patients [4]